Clinical Trial Update: Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating bortezomib in Waldenström's macroglobulinemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: NCIC Clinical Trials Group | Conditions: Lymphoma | Phase 2 | Status: COMPLETED